Clinuvel Pharmaceuticals - a market darling which has developed a drug for a rare skin disease for which it now faces competition from a Japanese rival - is facing a second strike and possible spill at its annual meeting.
Chairman Willem Blijdorp urged shareholders to back the board at the Wednesday’s AGM, arguing the board has taken steps to address concerns about the CEO’s pay which were raised at last year’s meeting by shareholders.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
